健康成人接种日本脑炎疫苗IXIARO®后免疫应答持久性:五年随访研究
本研究对健康成人接种日本脑炎疫苗IXIARO®后进行5年随访,评估保护性中和抗体的持久性,并按是否接种蜱传脑炎疫苗分层比较。基础免疫系列后4周,意向治疗人群PRNT50滴度≥1:10的比例为99%,5年后为81.6%;接种蜱传脑炎疫苗者各时间点保护率高于未接种者。未发现长期安全性问题。
要点
- 基础免疫后4周99%受试者PRNT50滴度≥1:10,5年后降至81.6%。
- 接种蜱传脑炎疫苗者5年保护率85.9%,未接种者63.8%。
- IXIARO®诱导的保护性滴度可持续至基础免疫后60个月。
核心结论
- IXIARO®基础免疫后可诱导保护性滴度并持续至60个月。
- 既往蜱传脑炎疫苗接种与日本脑炎保护性抗体持久性较高相关。
研究设计与样本
- 5年随访研究,纳入健康成人,按是否接种蜱传脑炎疫苗分层分析。
- 临床试验注册号NCT00596102。
主要发现
- 基础免疫系列后4周,意向治疗人群PRNT50滴度≥1:10比例为99%。
- 5年后该比例为81.6%。
- 接种蜱传脑炎疫苗者在第24、36、48、60月保护率分别为90.7%、91.7%、90.1%、85.9%。
- 未接种蜱传脑炎疫苗者相应时间点保护率分别为67.9%、71.9%、69.1%、63.8%。
- 未发现长期安全性问题。
关键数值与推荐
- 保护性中和抗体定义为PRNT50滴度≥1:10。
- 基础免疫后4周意向治疗人群保护率为99%,5年后为81.6%。
- 接种蜱传脑炎疫苗者第60月保护率85.9%,未接种者63.8%。
临床怎么用
- IXIARO®基础免疫后保护性抗体可维持至5年,支持长期保护预期。
- 评估日本脑炎疫苗免疫持久性时可考虑蜱传脑炎疫苗接种史的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunization with the Japanese encephalitis (JE) vaccine IXIARO® results in protective neutralizing antibody levels for one year. Since persistence of protective titer levels beyond one year was unknown, a 5 years follow-up study was conducted. Additionally, data were stratified to compare the persistence of protective neutralizing antibodies against JE in people with or without tick-borne encephalitis (TBE) vaccination. Four weeks after the primary series, the percentage of subjects with PRNT50 titer ≥1:10 in the intent-to-treat population was 99%; the rate after 5 years was 81.6%. By month 24, 36, 48 and 60, the percentages were still 90.7%, 91.7%, 90.1%, 85.9%, respectively in the population who had received TBE vaccine compared to 67.9%, 71.9%, 69.1%, 63.8% in the population who had not. No long-term safety concerns were identified. These data indicate that vaccination with IXIARO® is able to induce protective titers that persist up to 60 months after the primary immunization. Clinical trial registry number NCT00596102.
引用
- Taucher C, Kollaritsch H, Dubischar KL, et al. Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study. Vaccine. 2019. PMID: 30962094. doi:10.1016/j.vaccine.2019.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。